drugset / Trial / NCT05538585
A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicaftor and Navocaftor
RandomizedParallel-groupOpen-labelBasic science
Summary
Cystic Fibrosis (CF) is a rare, life-threatening, genetic disease that affects the lungs and digestive system, significantly impairing the quality of life, with those affected having a median age of death at 40. The objectives of this study are to assess the effect of food on the safety and pharmacokinetics of navocaftor and galicaftor.
Timeline
- Start
- 2022-09-27
- Primary completion
- 2022-12-21
- Completion
- 2022-12-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Galicaftor | Small molecule | — | Oral |
| Subject | Navocaftor | Small molecule | — | Oral |
Indications
No indication recorded.